scholarly journals Efficacy of Postoperative Adjuvant Chemotherapy According to Prognostic Factor in Patients with Stage III Colon Cancer

2014 ◽  
Vol 05 (08) ◽  
pp. 806-816 ◽  
Author(s):  
Kiichi Sugimoto ◽  
Kazuhiro Sakamoto ◽  
Yuichi Tomiki ◽  
Michitoshi Goto ◽  
Yutaka Kojima ◽  
...  
Keyword(s):  
Colon Cancer ◽  
Adjuvant Chemotherapy ◽  
Prognostic Factor ◽  
Stage Iii ◽  
Postoperative Adjuvant Chemotherapy ◽  
Stage Iii Colon Cancer

scholarly journals The Latest Update of Prognostic Factors of Stage III Colon Cancer Who Underwent Curative Operation and Postoperative Adjuvant Chemotherapy

2019 ◽  
Vol 104 (9-10) ◽  
pp. 446-452
Author(s):  
Keigo Yokoi ◽  
Masanori Naito ◽  
Keishi Yamashita ◽  
Satoru Ishii ◽  
Toshimichi Tanaka ◽  
...  
Keyword(s):  
Colon Cancer ◽  
Prognostic Factors ◽  
Adjuvant Chemotherapy ◽  
Poor Prognosis ◽  
Univariate Analysis ◽  
Stage Iii ◽  
Depth Of Invasion ◽  
Postoperative Adjuvant Chemotherapy ◽  
Free Survival ◽  
Stage Iii Colon Cancer

This study aimed to explore the predicting factor of the poor prognosis of stage III colon cancer. Adjuvant chemotherapy for stage III colon cancer has become popular. However, the choice of the optimal adjuvant chemotherapy regimen still remains unclear. A total of 135 patients with stage III colon cancer, treated with postoperative adjuvant chemotherapy from January 2007 to December 2012 at the Kitasato University East Hospital, were reviewed retrospectively in terms of clinicopathologic characteristics associated with survival and recurrence (median observation: 61 months). We used a multivariate Cox hazards model to identify independent prognostic factors in stage III colon cancer. Of the 135 patients, 38 had recurrence. Five-year overall survival was 83.9%, while 3-year recurrence-free survival was 72.8%. Oxaliplatin-containing adjuvant chemotherapy was almost exclusively applied to stage IIIB colon cancer. Univariate analysis of the negative prognostic factors were N2 (P = 0.0004); operation time (P = 0.0346); tumor size (P = 0.0092); depth of invasion (P = 0.005); histology (P = 0.0403); infiltration type (P < 0.0001); lymphatic permeation (ly3, P = 0.0001); and vascular permeation (v3, P = 0.0005). On multivariate analysis, the independent prognostic factors for relapse-free survival were v3 (P = 0.032) and N2 (P = 0.0216). Combination of the prognostic factors clearly stratified prognosis of stage III colon cancer patients, and those with either factor positive had a poor prognosis despite administration of adjuvant chemotherapy. Both v3 and pN2 may be critical prognostic factors in stage III colon cancer with adjuvant chemotherapy. This information would elucidate areas of concern in the present therapeutic strategy in stage III colon cancer.

scholarly journals Severe rhabdomyolysis related to oxaliplatin adjuvant therapy for colorectal cancer

2019 ◽  
Vol 12 (4) ◽  
pp. e228673 ◽  
Author(s):  
Ana Pissarra ◽  
Mariana Malheiro ◽  
Leonor Vasconcelos Matos ◽  
Ana Neto Plácido
Keyword(s):  
Colorectal Cancer ◽  
Colon Cancer ◽  
Adjuvant Chemotherapy ◽  
Stage Iii ◽  
Standard Chemotherapy ◽  
Postoperative Adjuvant Chemotherapy ◽  
Stage Iii Colon Cancer ◽  
Distal Muscle ◽  
Common Cancer ◽  
Resected Stage

Colorectal cancer is the third most common cancer in men and the second in women. The standard chemotherapy regiment in stage III colon cancer is based in oxaliplatin. The most common side effects include neutropenia, peripheral neuropathy, vomiting and diarrhoea. Rhabdomyolysis due to oxaliplatin is rare, and there are no established guidelines for managing this adverse event. This report describes a case of a 52-year-old man, with a resected stage III colon cancer that started postoperative adjuvant chemotherapy with capecitabine plus oxaliplatin. After the second cycle, the patient developed distal muscle pain and weakness, with a total inability to walk. Blood tests showed an elevated creatine kinase and renal injury. Severe drug-related rhabdomyolysis was diagnosed. The goal of this case report is to discuss the side effect of adjuvant chemotherapy, given its rarity and severity.

Preplanned initial safety analysis of ACTS-CC 02 trial: A large randomized phase III trial of SOX versus UFT/LV as adjuvant chemotherapy for high-risk stage III colon cancer.

2012 ◽  
Vol 30 (4_suppl) ◽  
pp. 572-572 ◽  
Author(s):  
Hiroya Takiuchi ◽  
Naohiro Tomita ◽  
Narikazu Boku ◽  
Toshiaki Watanabe ◽  
Kenjiro Kotake ◽  
...  
Keyword(s):  
Colon Cancer ◽  
High Risk ◽  
Adjuvant Chemotherapy ◽  
Adverse Events ◽  
Curative Resection ◽  
Phase Iii ◽  
Stage Iii ◽  
Postoperative Adjuvant Chemotherapy ◽  
Stage Iii Colon Cancer ◽  
To Receive

572 Background: The ACTS-CC 02 trial is designed to verify the superiority of postoperative adjuvant chemotherapy of S-1/Oxaliplatin (SOX) for patients with anyT, N2 colon cancer compared with UFT/Leucovorin (UFT/LV), which is one of standard adjuvant chemotherapies in Japan. To date, there have been no reported phase III trials evaluating SOX as postoperative adjuvant chemotherapy. This report presents initial safety data obtained from 50 patients who received SOX in the trial. Methods: Patients who underwent curative resection for anyT, N2 colon cancer were randomly assigned to receive either SOX (100 mg/m2 of oxaliplatin on day1, and 80 to 120 mg/day according to body surface area (BSA) of S-1 on days 1-14, every 21 days, 8 courses) or UFT/LV (300 to 600 mg/day according to BSA of UFT and 75 mg/day of LV on days 1-28, every 35 days, 5 courses). Data were collected from initial consecutive 50 patients assigned to the SOX group and analyzed when they were considered evaluable for safety as planned in the protocol. This ongoing trial is designed to accrue 1200 patients. As of September 15, 2011, 319 patients have been accrued. Results: Of 50 patients assigned to receive SOX, 48 were evaluable for safety. The median number of treatment courses was 5 (range: 1-8). The relative dose intensity of S-1 was 83.8% and that of oxaliplatin was 86.6%. Grade 3 adverse events were neutropenia (14.6%), thrombocytopenia (2.1%), ALT elevation (2.1%), diarrhea (8.3%), fatigue (2.1%), and peripheral sensory neuropathy (2.1%). Grade 4 adverse effects were not observed. Conclusions: In this initial safety analysis, the incidence and severity of adverse events with SOX were acceptable in patients with high risk stage III colon cancer after curative resection. Enrollment of patients is ongoing.

Sign in / Sign up

Export Citation Format

Share Document